Active in Medical Technology

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

... novel DACH platinum drug that has shown to be active in many solid tumors in human clinical studies. ... cancer trial that showed that ProLindac was more active than currently available platinum drugs in that ... a novel DACH platinum drug that has shown to be active in many solid tumors in human clinical studies. ...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

... Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). In the ... the findings that emerged in the serologically active subgroup of SLE patients at Week 52 in our Phase ... placebo plus standard of care, in serologically active (i.e., autoantibody-positive) patients with SLE. ...

Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial

... Exchange Limited) announced that its improved active transdermal delivery technology, which ... the venipuncture procedure were 16.4 mm for the active treatment versus 24.0 mm for the Placebo ... statistically lower VAS scores for the active group as compared to the Placebo group. In ...

Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets

... are indicated for the treatment of moderately active ulcerative colitis (UC), a form of inflammatory ... followed by periods of remission. Moderately active UC is characterized by tougher symptoms than mildly active UC. Asacol HD is proven to help treat these ...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

... to represent general population of sexually active young women TVC-naive included all women ... risk of HPV infection throughout their sexually active lives. Approximately 100 types of HPV have been ... and a leader in innovation. The company is active in the fields of vaccine research, development ...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... therapy for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis (AS). Upon ...

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

... --Orally active Enhancer of Human Nerve Growth Factor Has ... candidate, CXB909, is a small molecule, orally active agent that enhances the effects of nerve growth ... also includes CXB909, a small molecule, orally active agent for the prevention and treatment of ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment ... news for patients with moderately to severely active rheumatoid arthritis who have been previously ... anti-TNFs. The trial included 461 patients with active RA of 8.65 years mean duration. Discontinuation ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... L onal Antibody (GO-REVEAL) study, patients with active PsA were randomized to placebo (n=113), SIMPONI ... with at least 3 swollen and tender joints and active psoriatic skin lesions of at least two cm in ... The GO-RAISE trial included 356 patients with active ankylosing spondylitis. Patients were randomized ...

Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer

... that paclitaxel poliglumex may be a uniquely active and selective radiosensitizing therapeutic. Most ... tumor tissue with continual slow release of the active agent, paclitaxel," noted Jack Singer, M.D., ... chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable ...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

... 3b study of patients with moderately to severely active Crohn's disease having inadequate response to ... FDA for the treatment of moderately to severely active Crohn's disease for the reduction of the signs ... FDA for the treatment of moderately to severely active ulcerative colitis, in patients with an ...

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

... maximum plasma concentrations of amphetamine, the active medication. Other pharmacokinetic parameters ... plasma concentration and area under curve) of active medication were not altered for either VYVANSE or ... "In this study, the conversion of VYVANSE to its active form was not affected when coadministered with ...

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis

... Phase 2 proof-of-concept trial in patients with active rheumatoid arthritis (RA) receiving methotrexate ... Phase 2 study in RA enrolled 70 patients with active disease while on methotrexate. Patients in the ... placebo-controlled study in patients with active UC while continuing standard UC therapy is ...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

... option for adults with moderately to severely active rheumatoid arthritis and moderate to severe ... option for adults with moderately to severely active rheumatoid arthritis. Cimzia(R) is also approved ... in adult patients with moderate to severely active disease who have had an inadequate response to ...

FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia

... studies comparing Fanapt(TM) to placebo and active control in patients with schizophrenia, as well ... Fanapt(TM) (24 mg/day) compared to placebo and an active control (Geodon(R)), the 24 mg/day Fanapt(TM) ... and 20-24 mg/day) compared to placebo and an active control (Risperdal(R)), both doses of Fanapt(TM) ...

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis

... reduction of at least 70% in the mean number of active T1 gadolinium-enhanced lesions per subject per scan, the mean number of active T2 lesions per subject per scan, as well as the ... ON To Rebif New Formulation in Patients With active Relapsing Disease) study: a Phase II ...

Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R)

... at the SAWC include: active Leptospermum Honey - A Debriding ... Baylor Health Care System, TX) Use of active Leptospermum Honey Dressings in the Home ... (Tim Larson, Cleveland Clinic, OH) active Leptospermum Honey: Treatment for Various ...

Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

... by 38 Percent Compared to Placebo - - First active Cellular Immunotherapy for Cancer to Prolong ... cancer and represents the first in a new class of active cellular immunotherapies (ACI) specifically ... and validate the potential of our pipeline of active cellular immunotherapy product candidates that ...

AUA Guideline: Full Kidney Removal Not Necessary for All Kidney Tumors

... such as partial nephrectomy, thermal ablation and active surveillance, minimize these risks and are viable ... for the patient at high surgical risk who wants active treatment and accepts the need for long-term ... the current thermal ablation literature. active Surveillance: ...

Men Treated for Localized Prostate Cancer Could Benefit From Pomegranate Juice Consumption

... daily. Currently, in the sixth year of treatment, active patients who remain on the study have a median ... 0.06 to 0.024. Researchers compared active patients, who remain on the study, with ... the decline in median PSA slope were greater in active patients when compared to non-active patients. ...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

... and Vectibix(R) (panitumumab) they were highly active against KRAS-and BRAF-mutated human colorectal ... cetuximab(2,3) and panitumumab(3,4) are not active in colorectal cancer patients with tumor cells ... a relevant non-human primate species suggest that active serum levels of the cetuximab-based BiTE antibody ...

March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots

... information, 800-333-9037, extension 9771. active at 50? Still Prime for Knee Repair Surgery ... knee injury, doesn't have to permanently sideline active adults age 50 and older, according to the March ... More people 50 and older are leading active lives, which makes them good candidates for ...

Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories

... efficacy to the vehicle gel and either individual active ingredient, while demonstrating excellent ... were <1 (1=mild) and comparable to individual active ingredients and vehicle. Patient ... efficacy to the vehicle gel and either individual active ingredient, while demonstrating excellent ...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

... options and had tumors that were functionally active (i.e., tumors that secrete various hormones and ... a disease caused by a pituitary adenoma. The active ingredient in Sandostatin LAR, octreotide ... and 600,000 patient years of experience, the active ingredient in Sandostatin LAR has achieved a ...

Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)

... activity in EXPAREL treated patients compared to active control -- A positive trend toward lower opioid use in all EXPAREL groups compared to active control -- More patients who received EXPAREL avoided opioids altogether, compared to active control. In addition, the study ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... with 84 patients, of which 24 remain on active treatment. In his presentation, Dr. Richardson ... stated, "Perifosine appears to be particularly active with durable responses when combined with ... reached at 16.8 months. Ten patients remain on active treatment. Abstract 1010: Final Results ...

Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin

... this trial, delafloxacin was shown to be the more active compound overall, including its activity against ... is developing novel classes of antibiotics active against multi-drug resistant Gram-negative ... is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, ...

Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress

... EXPAREL 300mg and 450mg patient groups versus active control, 6.4 vs. 7.8 pain intensity and 6.1 vs. ... and vomiting occurrence was 40% lower than in the active control group. Approximately 8% of ... use versus zero percent (0%) of patients in the active control group. No ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... adverse reactions in nursing infants. Sexually active female patients taking Gleevec should use ... should not be used during pregnancy. Sexually active female patients should use effective ... drugs. Zometa contains the same active ingredient as found in Reclast(R) (zoledronic ...

CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients

... indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response ... is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults ... idiopathic arthritis Treatment of active polyarticular juvenile idiopathic arthritis ...

Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease

... Marks the First Time a European Patient with active Celiac Disease has Enrolled in a Clinical Trial ... regulator, for the treatment of patients with active celiac disease (CD). The global ... and tolerability of larazotide acetate in 106 active CD subjects adhering to a gluten-free diet, ...

Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD

... (e.g., bronchitis) was generally higher for all active treatment groups, except SYMBICORT 80/4.5 mcg, ... (e.g., bronchitis) was slightly higher in the active treatment groups compared to placebo.(4) -- The ... beta2-adrenergic agonist), one of the active ingredients in SYMBICORT. SYMBICORT is not ...

CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years

... with methotrexate (MTX) in the treatment of active rheumatoid arthritis who did not adequately ... the prevention of joint damage in patients with active RA. Patients completing RAPID 1 through 52 weeks ... O11) phase III study, 220 adult patients with active RA who had previously failed at least ...

Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA

... - 12:15 pm) -- F1-2060: MICs of TR-700, the active Moiety of the Novel Oxazolidinone Prodrug ... F1-2062: In Vitro Pharmacodynamics of TR-700, the active Moiety of Prodrug TR-701, a Novel ... -- F1-2069: Relative Potency of TR-700, the active Moiety of Prodrug TR-701, Against Selected ...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

... no new safety signals observed over 2.5 years of active treatment. Pharmacoeconomics Study (Abstract ... in adult patients with moderate to severe active disease who have had an inadequate response ... receiving CIMZIA for signs and symptoms of active tuberculosis, including patients who tested ...

New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study

... FDA for the treatment of moderately to severely active Crohn's disease for the reduction of the signs ... in patients with moderately to severely active RA, when administered in combination with ... -- Reducing signs and symptoms in patients with active AS. -- Reducing signs and symptoms and inducing ...

CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients

... in adult patients with moderate to severe active disease who have an inadequate response to ... the intestinal mucosal lesions in patients with active Crohn's disease. CIMZIA was administered ... in adult patients with moderate to severe active disease who have had an inadequate response ...

Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial

... the safety and efficacy of the investigational active cellular immunotherapy PROVENGE(R) (sipuleucel-T) ... reported in our previous trials). About active Cellular Immunotherapy with PROVENGE PROVENGE ... a specific long-lasting response against cancer. active cellular immunotherapy holds promise because it ...

New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes

... known or suspected estrogen-dependent neoplasia; active or history of deep vein thrombosis (DVT) or pulmonary embolism; active or recent arterial thromboembolic disease; liver ... manufacturing and marketing of pharmaceuticals, active pharmaceutical ingredients and diagnostic tests ...

QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy

... vaginal atrophy symptoms among sexually active and non-sexually active postmenopausal women; results presented today ... for both sexually active and non-sexually active respondents. A majority of women in the survey ...